Annual Report and Accounts

RNS Number : 1392A
Alliance Pharma PLC
27 March 2012
 



For immediate release

27 March 2012

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Annual Report and Accounts

 

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to announce that its 2011 Annual Report and Accounts are now available on the Company's website at www.alliancepharma.co.uk.

 

Printed copies will be posted to shareholders in April and may also be requested by email at ir@alliancepharma.co.uk.

 

 

 

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0) 1249 466966

John Dawson, Chief Executive


Richard Wright, Finance Director


www.alliancepharma.co.uk


 

Buchanan

 

+ 44 (0) 20 7466 5000

Mark Court / Jessica Fontaine




Numis Securities Limited

+ 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Oliver Cardigan


Corporate Broking: David Poutney


 

Notes to editors:

 

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

 

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections.  Alliance's sales are mainly prescription driven.  Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

 

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSDDLBLLXFEBBE
UK 100

Latest directors dealings